ReviewThe Journal of clinical and aesthetic dermatology2024
Treatment Options for Onychomycosis: Efficacy, Side Effects, Adherence, Financial Considerations, and Ethics.
Review in The Journal of clinical and aesthetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 16 citations in OpenAlex.
- Trial
- Antifungal pulse therapy for onychomycosis: a narrative review.European journal of clinical pharmacology · 2026Review
- Multifunctional Activity ofPlants (Basel, Switzerland) · 2026Article
- Formulation and development of thymoquinone-loaded ufasome hydrogel for effective treatment of onychomycosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Comparative Retrospective Evaluation of the Clinical and Mycological Efficacy of 69% Nitric Acid, 1064 nm Nd:YAG Laser, and Their Combination in the Treatment ofInfectious disease reports · 2025Article
- Harnessing nd: YAG laser technology to combat antifungal resistance in yeast-driven onychomycosis.Lasers in medical science · 2025Article
- Treating Onychomycosis with Efinaconazole: Considerations for Diverse Patient Groups.Journal of fungi (Basel, Switzerland) · 2025Review
- Epidemiological Trends and Clinical Features ofJournal of Korean medical science · 2025Article
- Retrospective study of onychomycosis patients treated with ciclopirox 8% HPCH and oral antifungals applying artificial intelligence to electronic health records.Scientific reports · 2025Article
- An Assessment of the Antifungal Efficacy of a Novel Topical Onychomycosis Treatment Using Human Nail and Skin Infection Models.Journal of fungi (Basel, Switzerland) · 2025Article
- Long term efficacy of Nd: Yag laser treatment for onychomycosis : A debridement option for dermatophytoma.Lasers in medical science · 2025Article
- Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC advances · 2025Review
- Red-Laser Photodynamic Therapy with Toluidine Blue Gel as an Adjuvant to Topical Antifungal Treatments for Onychomycosis in Patients with Diabetes: A Prospective Case Series.Journal of clinical medicine · 2025Article
- Analysis of Causative Factors and Potential Predictors of Onychomycosis: A Retrospective Single-Center Study in Poland.Journal of fungi (Basel, Switzerland) · 2025Article
- Addressing filamentous fungi-related onychomycosis in the era of antifungal resistance: assessment ofCurrent medical mycology · 2025Article
- Safety and efficacy of the swift microwave device in patients with mild-to-moderate onychomycosis: Protocol of an open-label, randomized, dose-finding pilot study.Skin health and disease · 2024Article
- Diabetic Foot and Fungal Infections: Etiology and Management from a Dermatologic Perspective.Journal of fungi (Basel, Switzerland) · 2024Review
- Laser Treatment in Nail Disorders: A Comprehensive Review.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Onychomycosis is a fungal infection of the nail unit that affects a large patient population globally. Onychomycosis, or tinea unguium, has a benign chronic clinical course; however, it can cause complications in certain patient populations suffering from diabetes and peripheral vascular disease. As nails grow slowly, onychomycosis requires a lengthy treatment plan, and choosing appropriate treatments can be challenging. There are a variety of treatment modalities available for patients including topical, oral, laser, light therapy, procedures such as avulsion and matrixectomy, supplements, over-the-counter medication, and plasma therapy that can be used as monotherapy or in combination for patient satisfaction. Objective: We sought to review treatment options for onychomycosis, taking into consideration the efficacy, side effect profiles, practicality of treatment (adherence), and costs to help healthcare providers offer ethically appropriate treatment regimens to their patients. Methods: A literature search was conducted using electronic databases (PubMed, Embase, Medline, CINAHL, EBSCO) and textbooks, in addition to the clinical experiences of the authors and other practitioners in treating onychomycosis, and a summary of the findings are presented here. Results: Although topical (efinaconazole, tavaborole, ciclopirox), oral (terbinafine, itraconazole), and laser (1064nm Nd:YAG lasers, both short-pulsed and Q-switched lasers, carbon dioxide lasers, and the diode 870, 930nm) are the current Food and Drug Administration (FDA)-approved treatments for onychomycosis, they are just a fraction of available treatment options. New and emerging therapies including new topical and oral medications, combination therapy, photodynamic light therapy, procedural, supplements, over-the-counter medication, and plasma therapy are discussed in our review. Discussion: Onychomycosis has high reinfection and recurrence rates, and the treatment remains challenging as treatment selection involves ethical, evidence-based decision-making and consideration of each individual patient's needs, adherence, budget, the extent of quality of life discomfort, and aesthetic goals, independent of potential financial benefits to the clinicians.
Indexed as
Identifiers
38495549PMC10941855W4394759618What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.